Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study
Year: 2026
Type: article
Source: International Journal of Urology
DOI: 10.1111/iju.70455
Institutions: Fudan University Shanghai Cancer Center, University of Malaya, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Keimyung University Daegu Dongsan Hospital, Keimyung University Dongsan Hospital, Keimyung University, Chang Gung University, Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Macquarie University, University College London, University of British Columbia, Johnson & Johnson (United States), Johnson & Johnson (Singapore), The University of Melbourne, Peter MacCallum Cancer Centre
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Funder: Johnson and Johnson
OpenAlex ID: W7155193853